Tag Archives: Genentech

Advisory Panel Rejects Avastin For Breast Cancer Treatment

By George Koroneos | Published: July 21, 2010
An FDA advisory panel on Tuesday voted 12–1 to discontinue Avastin (bevacizumab) as a treatment for advanced breast cancer due to post-market studies stating that the treatment does not to increase patient lifespan by any significant length of time. This is a huge problem for Roche who purchased the treatment as part of its merger with [...]
Posted in FDA, Safety | Also tagged , , , , , , , | Leave a comment

Avastin Study Shows Promising Data for Cancer Patients

By George Koroneos | Published: June 8, 2010
Genentech released the results of its Phase III Avastin study showing that women that take the ovarian cancer treatment in tandem with chemotherapy had a 39 percent improvement in the likelihood of living longer without the disease worsening than patients being treated with just chemotherapy. The data was released at the annual meeting of American Society [...]
Posted in R&D | Also tagged , , , | Leave a comment

Hot Topics at HBA

By Brittany Agro | Published: November 20, 2009
The 2009 Healthcare Businesswomen’s Association leadership conference is officially underway in sunny California. Last night, festivities got underway with a welcome reception for attendees followed by a “Taste of San Francisco,” which featured lively entertainment and regional cuisine. I had the opportunity to catch up with a few seasoned participants who are widely known throughout the [...]
Posted in Events | Also tagged , , | 1 Comment

Avastin Gets Green Light for Use in Kidney Cancer

By George Koroneos | Published: August 5, 2009
Image by Getty Images via Daylife Score another win for Genentech and its cancer treatment Avastin (bevacizumab). On Monday, the biotech giant, now owned entirely by Roche, announced that FDA has approved the drug for kidney cancer. Avastin blocks new blood vessels from forming and supplying tumors with the nutrients they need to grow and spread to [...]
Posted in News | Also tagged , , , , , , | Leave a comment

Roche and Genentech Seal the Deal
for $46.8 Billion

By George Koroneos | Published: March 12, 2009
After months and months of back and forth over the true value of Genentech, Roche finally got the good news it’s been looking for: Genentech’s board of directors, this morning, approved Roche’s latest offer of $46.8 billion ($95 per share) to acquire all shares of the biotech giant. Roche plans to keep the Genentech site in [...]
Posted in Biotech | Also tagged , , , , , | 1 Comment